Real-world evidence from the ENEIDA Registry suggests that in clinical practice, TNF inhibitors are frequently used for the prevention of postoperative occurrence of IBD in patients experienced with such agents and who are often receiving concomitant immunosuppressants.160 Findings from this registry demonstrate that infliximab and adalimumab have similar efficacy for the prevention of postoperative recurrence, and that findings were consistent with results obtained in randomized controlled trials.160. Here, TNF is linked to inflammatory bowel disease.